Compare

Twist Bioscience Corp vs Tarsus Pharmaceuticals, Inc. vs ADMA Biologics, Inc. vs Immunocore Holdings plc

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearTwist Bioscience Corp
TWST
Tarsus Pharmaceuticals, Inc.
TARS
ADMA Biologics, Inc.
ADMA
Immunocore Holdings plc
IMCR
Year ended2026-09-302025-12-312025-12-312025-12-31
Revenue$459.43M$451.36M$510.17M$400.02M
Revenue growth (YoY)+22.0%+146.7%+19.6%+29.0%
Gross margin52.4% (computed)n/a57.4%n/a
Operating margin-30.4%-15.7%37.5%-11.3%
Net margin-28.3%-14.7%28.8%-8.9%
Net income-$130.20M-$66.42M$146.93M-$35.51M
EPS (Diluted)-$2.08-$1.59$0.60-$0.71
Operating cash flow-$41.43M-$12.45M$50.40M-$10.71M
Free cash flow-$89.01M-$22.31M$27.82M-$15.05M
Cash & equivalents$533.99M$183.64M$87.63M$467.71M
Total assets$1.12B$562.16M$624.24M$1.07B
Total liabilities$233.79M$218.73M$146.92M$686.24M
Shareholders' equity$888.02M$343.43M$477.32M$381.03M
Return on year-end equity-14.7%-19.3%30.8%-9.3%
Shares outstanding67.81M42.55M237.87M50.69M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearTwist Bioscience CorpTarsus Pharmaceuticals, Inc.ADMA Biologics, Inc.Immunocore Holdings plc
Latest$459.43M
Ended 2026-09-30
$451.36M
Ended 2025-12-31
$510.17M
Ended 2025-12-31
$400.02M
Ended 2025-12-31
1 year earlier$376.57M
Ended 2025-09-30
$182.95M
Ended 2024-12-31
$426.45M
Ended 2024-12-31
$310.20M
Ended 2024-12-31
2 years earlier$312.97M
Ended 2024-09-30
$17.45M
Ended 2023-12-31
$258.21M
Ended 2023-12-31
$249.43M
Ended 2023-12-31
3 years earlier$245.11M
Ended 2023-09-30
$25.82M
Ended 2022-12-31
$154.08M
Ended 2022-12-31
$174.36M
Ended 2022-12-31
4 years earlier$203.56M
Ended 2022-09-30
$57.03M
Ended 2021-12-31
$80.94M
Ended 2021-12-31
$36.48M
Ended 2021-12-31